

THE LANCET **Oncology**

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.


Supplement to: Armstrong AJ, Halabi S, Eisen T, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. *Lancet Oncol* 2016; published online Jan 12. [http://dx.doi.org/10.1016/S1470-2045\(15\)00515-X](http://dx.doi.org/10.1016/S1470-2045(15)00515-X).

Appendix

Principal Investigator	Site	Patients Enrolled
Tim Eisen	University of Cambridge, Cambridge, United Kingdom	15
Walter M. Stadler	University of Chicago, Chicago, IL USA	13
Robert J. Jones	The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom	13
Jorge A. Garcia	Cleveland Clinic, Cleveland, OH USA	12
Andrew J. Armstrong	Duke University and the Duke Cancer Institute, Durham, NC	11
Ulka N. Vaishampayan	Karmanos Cancer Institute, Wayne State University, Detroit, MI USA	10
Joel Picus	Washington University in St. Louis, St. Louis, MO USA	6
Robert E. Hawkins	Christie Cancer Research Centre, Manchester, United Kingdom	5
John D. Hainsworth	Sarah Cannon Research Institute, Nashville, TN USA	4
Christian K. Kollmannsberger	BC Cancer Agency, Vancouver Cancer Centre, Vancouver, BC Canada	4
Theodore F. Logan	Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN USA	3
Igor Puzanov	Vanderbilt University Medical Center, Nashville, TN USA	3
Lisa M. Pickering	Royal Marsden Hospital, London, United Kingdom	3
Christopher W. Ryan	Oregon Health & Science University, OHSU Knight Cancer Institute, Portland, OR USA	2
Andrew Protheroe	University of Oxford Medical Oncology Department, Oxford, United Kingdom	2
Mary Mackenzie	London Health Sciences Center, London Ontario Canada	1
Omar Din	Cancer Clinical Trial Centre, Weston Park Hospital, Sheffield, UK	1

Table 1. List of participating sites and accruals.


Overall Survival Curves by Motzer Criteria




Number of Patients at Risk

0	29	16	11	6	5	0	0
1-2	64	25	14	8	6	6	2
3+	15	6	0	0	0	0	0

Supplementary Figure 1. Kaplan-Meier estimates of PFS according to 2002 MSKCC risk groups.



Supplementary Figure 2. Waterfall plots of best overall RECIST 1.1 response according to treatment group. Tumor shrinkage post-treatment is represented below the x-axis, while tumor growth is portrayed as above the x-axis, and patients are arranged in increasing order on the x-axis.



Supplementary Figure 3. Forest plot of toxicity, with relative risks of a given toxicity displayed with sunitinib as the reference group (i.e. $RR > 1.0$ indicates a higher risk of developing a toxicity for everolimus treated patients).

A. Overall FACT-KSI.

Treatment / Visit	n	Mean (SD)	Observed		n	Change from Randomization		
			Median (Q1, Q3)	Min, Max		Mean (SD)	Median (Q1, Q3)	Min, Max
Everolimus								
Randomization	54	46.5 (9.20)	47.5 (42.9, 53.0)	23.0, 59.0				
Cycle 3	31	43.6 (8.63)	44.0 (37.0, 50.0)	25.0, 60.0	30	-3.5 (9.61)	-4.5 (-9.0, 1.0)	-25.0, 28.0
Cycle 6	13	47.2 (6.64)	49.0 (42.0, 51.0)	38.0, 60.0	13	-4.4 (6.37)	-2.0 (-9.0, 1.0)	-18.5, 4.0
End of Treatment	33	41.5 (11.42)	43.9 (32.0, 50.0)	15.0, 59.0	32	-6.6 (7.83)	-7.5 (-12.4, -2.0)	-19.0, 11.0
Sunitinib								
Randomization	47	43.6 (7.78)	45.0 (39.0, 49.0)	26.8, 56.0				
Cycle 3	33	42.7 (8.46)	43.0 (36.4, 49.0)	22.5, 59.0	31	-0.9 (7.19)	-1.0 (-4.5, 4.1)	-23.6, 11.0
Cycle 6	19	41.6 (9.18)	44.0 (35.0, 48.0)	27.0, 57.0	17	-2.1 (6.69)	-1.0 (-5.0, 1.0)	-20.0, 8.3
End of Treatment	31	39.4 (10.02)	41.8 (31.0, 48.0)	23.0, 56.0	30	-6.4 (10.04)	-5.0 (-12.0, 1.0)	-27.0, 9.0
Overall								
Randomization	101	45.2 (8.65)	46.0 (41.0, 51.0)	23.0, 59.0				
Cycle 3	64	43.1 (8.49)	43.0 (36.7, 49.5)	22.5, 60.0	61	-2.2 (8.49)	-3.0 (-7.0, 2.0)	-25.0, 28.0
Cycle 6	32	43.9 (8.59)	44.5 (37.0, 50.0)	27.0, 60.0	30	-3.1 (6.55)	-2.0 (-7.0, 1.0)	-20.0, 8.3
End of Treatment	64	40.5 (10.74)	42.0 (31.5, 49.5)	15.0, 59.0	62	-6.5 (8.89)	-5.5 (-12.0, -2.0)	-27.0, 11.0

B. FACT-KSI Disease related symptoms (DRS) subscale.

Treatment / Visit	n	Mean (SD)	Observed		n	Change from Randomization		
			Median (Q1, Q3)	Min, Max		Mean (SD)	Median (Q1, Q3)	Min, Max
Everolimus								
Randomization	54	29.9 (5.42)	31.0 (28.0, 34.0)	17.0, 36.0				
Cycle 3	31	27.7 (5.52)	29.0 (24.0, 32.0)	16.0, 36.0	30	-2.6 (6.27)	-2.0 (-5.0, 1.0)	-19.1, 15.0
Cycle 6	13	29.8 (3.76)	29.0 (27.0, 32.0)	22.0, 36.0	13	-2.5 (4.77)	-2.0 (-5.0, 1.0)	-14.0, 4.0
End of Treatment	33	26.6 (6.85)	28.0 (23.0, 32.0)	10.3, 36.0	32	-4.6 (4.03)	-4.0 (-7.4, -2.0)	-16.0, 3.0
Sunitinib								
Randomization	47	28.9 (4.97)	29.0 (25.0, 33.0)	15.0, 36.0				
Cycle 3	33	28.3 (5.01)	29.0 (25.9, 32.0)	12.4, 36.0	31	-0.1 (5.42)	-1.0 (-3.1, 3.0)	-18.6, 11.0
Cycle 6	19	27.6 (4.37)	27.0 (25.0, 31.0)	19.0, 35.0	17	-0.4 (5.23)	1.0 (-3.0, 3.0)	-11.0, 7.0
End of Treatment	31	26.6 (6.13)	28.0 (22.0, 32.0)	12.0, 35.0	30	-3.3 (6.30)	-2.0 (-5.0, 0.0)	-18.0, 8.0
Overall								
Randomization	101	29.4 (5.22)	31.0 (26.0, 34.0)	15.0, 36.0				
Cycle 3	64	28.0 (5.23)	29.0 (24.9, 32.0)	12.4, 36.0	61	-1.3 (5.93)	-1.0 (-4.0, 2.0)	-19.1, 15.0
Cycle 6	32	28.5 (4.22)	28.0 (26.5, 32.0)	19.0, 36.0	30	-1.3 (5.07)	-1.5 (-4.0, 2.0)	-14.0, 7.0
End of Treatment	64	26.6 (6.46)	28.0 (22.5, 32.0)	10.3, 36.0	62	-4.0 (5.25)	-3.0 (-7.0, -1.0)	-18.0, 8.0

Supplementary Table 2. Quality of life Data based on FACT-KSI overall (A) and the disease related symptom (DRS) subscale (B).